Abstract:Background: Transesophageal echocardiograms (TEEs) performed during transcatheter structural cardiac interventions may result in greater complications than those performed in the nonoperative setting or even those performed during cardiac surgery. However, there are limited data on complications associated with TEE during these procedures. We evaluated the prevalence of major complications among these patients in the United States. Methods: A retrospective cohort study was conducted using an electronic health record database (TriNetX Research Network) from large academic medical centers across the United States for patients undergoing TEE during transcatheter structural interventions from January 2012 to January 2022. Using the American Society of Echocardiography-endorsed International Statistical Classification of Diseases and Related Health Problems Clinical Modifications (10th edition) codes, patients undergoing TEE during a transcatheter structural cardiac intervention, including transaortic, mitral or tricuspid valve repair, left atrial appendage occlusion, atrial septal defect closure, patent foramen ovale closure, and paravalvular leak repair, were identified. The primary outcome was major complications within 72 hours of the procedure (composite of bleeding and esophageal and upper respiratory tract injury). The secondary aim was the frequency of major complications, death, or cardiac arrest within 72 hours in patients who completed intraoperative TEE during surgical valve replacement. Results: Among 12,043 adult patients (mean age, 74 years old; 42% female) undergoing TEE for transcatheter structural cardiac interventions, 429 (3.6%) patients had a major complication. Complication frequency was higher in patients on anticoagulation or antiplatelet therapy compared with those not on therapy (3.9% vs 0.5%; risk ratio [RR] = 8.09, P < .001). Compared with those patients <65 years of age, patients ≥65 years of age had a higher frequency of major complications (3.9% vs 2.2%; RR = 1.75, P < .001). Complication frequency was similar among male and female patients (3.5% vs 3.7%; RR = 0.96, P = .67). Among 28,848 patients who completed surgical valve replacement with TEE guidance, 728 (2.5%) experienced a major complication. Conclusions: This study found that more than 3% of patients undergoing TEE during transcatheter structural cardiac interventions have a major complication, which is more common among those on anticoagulant or antiplatelet therapy or who are elderly. With a shift of poor surgical candidates to less invasive percutaneous procedures, the future of TEE-guided procedures relies on comprehensive risk discussion and updating practices beyond conventional methods to minimize risk for TEE-related complications.

Antithrombotic therapy for transcatheter structural heart intervention

Antithrombotic Therapy Following Structural Heart Disease Interventions: Current Status and Future Directions

Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

High Bleeding Risk in Patients Undergoing Coronary and Structural Heart Interventions

Structural heart transcatheter interventions in orthotopic cardiac transplant and left ventricular assist devices recipients: A nationwide study

Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review

Recent developments and controversies in transcatheter aortic valve implantation

Transcatheter Structural Heart Disease Interventions and Concomitant Left Atrial Appendage Occlusion: A State-of-the-Art Review

Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum

Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention

Vascular Complications in the Era of Transcatheter Treatment of Adult Structural Heart Disease: A Single-Center Early Experience

Antithrombotic Therapy in Patients Undergoing Percutaneous Left Atrial Appendage Occlusion

Transcatheter Tricuspid Valve Interventions: A Triumph for Transcatheter Procedures?

Research progress of antithrombotic therapy after transcatheter aortic valve implantation

Current issues in transcatheter aortic valve replacement

Complications Associated With Transesophageal Echocardiography in Transcatheter Structural Cardiac Interventions

Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy

Interventional therapy for venous thromboembolism

Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program

Emerging Transcatheter Therapies for Valvular Heart Disease: Focus on Mitral and Tricuspid Valve Procedures